

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2017**

	Note	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
INCOME FROM:					
Donations and legacies	2	472,214	142,521	614,735	474,223
Charitable activities	3	126,204	312,379	438,583	372,575
Investments	4	772	-	772	2,325
TOTAL INCOME		599,190	454,900	1,054,090	849,123
EXPENDITURE ON:					
Raising funds	5	243,218	-	243,218	245,133
Charitable activities:					
Restructuring costs	6	23,522	-	23,522	59,231
Other charitable activities	7	173,084	454,900	627,984	826,422
TOTAL EXPENDITURE		439,824	454,900	894,724	1,130,786
NET INCOME/(EXPENDITURE)		159,366	-	159,366	(281,663)
NET MOVEMENT IN FUNDS		159,366	-	159,366	(281,663)
RECONCILIATION OF FUNDS:					
Total funds at 1 January 2017	17	288,731	-	288,731	570,394
TOTAL FUNDS AT 31 DECEMBER 2017		448,097	-	448,097	288,731

All activities relate to continuing operations.

The Statement of Financial Activities includes all gains and losses recognised in the year.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)
REGISTERED NUMBER: 57125

BALANCE SHEET
AS AT 31 DECEMBER 2017


	Note	€	2017 €	€	2016 €
FIXED ASSETS					
Tangible assets	13		1,836		4,980
CURRENT ASSETS					
Stocks	14	5,803		9,152	
Debtors	15	71,537		138,883	
Cash at bank and in hand	20	651,976		421,193	
		<u>729,316</u>		<u>569,228</u>	
CREDITORS: amounts falling due within one year	16	(283,055)		(285,477)	
NET CURRENT ASSETS			446,261		283,751
NET ASSETS			448,097		288,731
CHARITY FUNDS					
Unrestricted funds	17		448,097		288,731
TOTAL FUNDS			448,097		288,731

The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of .

The financial statements were approved and authorised for issue by the Directors on _____ and signed on their behalf on _____



Oliver Carroll
 Director



Allan Kearns
 Director

The notes on pages 17 to 33 form part of these financial statements.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2017

	Note	2017 €	2016 €
Net cash inflow/(outflow) from operating activities			
Net cash provided by/(used in) operating activities	19	<u>230,011</u>	<u>(231,024)</u>
Cash flows from investing activities:			
Bank deposit interest received	4	<u>772</u>	<u>2,325</u>
Net cash provided by investing activities		<u>772</u>	<u>2,325</u>
Change in cash and cash equivalents in the year		230,783	(228,699)
Cash and cash equivalents brought forward	20	<u>421,193</u>	<u>649,892</u>
Cash and cash equivalents carried forward	20	<u><u>651,976</u></u>	<u><u>421,193</u></u>

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

1. ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the financial statements.

1.1 General Information

These financial statements comprising the Statement of Financial Activities, the Balance Sheet, the Statement of Cashflows and the related notes constitute the individual financial statements of the Asthma Society of Ireland for the financial year ended 31 December 2017.

Asthma Society of Ireland is a Company Limited by Guarantee and not having a share capital (registered under Part 18 of Companies Act 2014), incorporated in the Republic of Ireland. The nature of the company's operations and its principal activities are set out in the Director's Report on pages 2 to 8.

Currency

The financial statements have been presented in Euro (€) which is also the functional currency of the company.

1.2 Basis of preparation of financial statements

The financial statements have been prepared on a going concern basis, in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2014

Asthma Society of Ireland meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

1.3 Company status

The Company is a Company limited by guarantee and does not have a share capital. The members of the Company are the Directors named on page 1. The liability of members is limited as defined in the Company's Memorandum of Association and shall not exceed €5 in the event of a winding up or dissolution of the charitable company.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

1. ACCOUNTING POLICIES (continued)

1.4 Going concern

The financial statements have been prepared on a going concern basis which assumes the Society has the ability to meet its liabilities as they fall due and will continue in operational existence for the foreseeable future.

The Society's annual income dropped considerably each year from 2013 to 2016, primarily as a result of the Government's decision to phase out the Charitable Lotteries Fund. During this period the Society used its reserves to invest in new fundraising streams. In 2016, it also significantly reduced its cost base through restructuring. As a result, the Society has reported a surplus of €159,366 for 2017 compared with a deficit of €281,663 in 2016. The Society has opening reserves at the start of 2018 of €448,097 which is in excess of the minimum required by the Board's reserves policy.

The 2018 budget approved by the directors provides for a surplus in 2018. This will leave the Society with opening reserves at the start of 2019, which, combined with its revised operational plan, in the opinion of the directors, demonstrate the Society's ability to continue comfortably as a going concern.

The financial statements do not contain any adjustments that may be necessary should the going concern basis of preparation be inappropriate.

1.5 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Directors in furtherance of the general objectives of the Company and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the Directors for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

1. ACCOUNTING POLICIES (continued)

1.6 Incoming resources

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the Company is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the Company has been notified of the executor's intention to make a distribution. Where legacies have been notified to the Company, or the Company is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the Company where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

Donated services or facilities are recognised when the Company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the Friends is not recognised and refer to the Directors' report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Company which is the amount the Company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

1.7 Resources expended

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the Company and include project management carried out at the Company's offices on Amiens Street. Governance costs are those incurred in connection with administration of the Company and compliance with constitutional and statutory requirements.

All expenditure is inclusive of irrecoverable VAT.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

1. ACCOUNTING POLICIES (continued)

1.8 Tangible fixed assets and depreciation

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures and fittings	-	20% straight line
Office equipment	-	10% straight line
Website development	-	33% straight line

The residual value and useful lives of tangible fixed assets are considered annually for indicators that these may have changed. Where such indicators are present, a review will be carried out of the residual value, depreciation method and useful lives, and these will be amended if necessary. Changes in depreciation rates arising from this review are accounted for prospectively over the remaining useful lives of the assets.

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities incorporating income and expenditure account.

1.9 Operating leases

Rentals under operating leases are charged to the Statement of Financial Activities on a straight line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight line basis over the period until the date the rent is expected to be adjusted to the prevailing market rate.

1.10 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.11 Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks.

1.12 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.13 Cash and cash equivalents

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to insignificant risk of change in value.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

1. ACCOUNTING POLICIES (continued)

1.14 Other financial liabilities

Trade creditors are measured at invoice price, unless payment is deferred beyond normal business terms or is financed at a rate of interest that is not market rate. In this case the arrangement constitutes a financing transaction and the financial liability is measured at the present value of future payments discounted at a market rate of interest for a similar debt instrument.

1.15 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.16 Provisions

Provisions are recognised when the company has a present legal or constructive obligation as a result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount of the obligation can be estimated reliably.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to passage of time is recognised as a finance cost within expenditure on charitable activities.

1.17 Pensions

The Company operates a defined contribution pension scheme. Retirement benefit contributions in respect of the scheme for employees are charged to the statement of financial activities as they become payable in accordance with the rules of the schemes. The assets are held separately from those of the company in an independently administered fund. Differences between the amounts charged in the statement of financial activities and payments made to retirement benefit schemes are treated as assets or liabilities.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

1. ACCOUNTING POLICIES (continued)

1.18 Critical accounting estimates and areas of judgement

In the application of the charity's accounting policies, which are described above, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Going concern

The directors have prepared budgets and cashflows for a period of at least 12 months from the date of approval of the financial statements which demonstrate that there is no material uncertainty regarding the charity's ability to meet its liabilities as they fall due and to continue as a going concern. On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis.

2. DONATIONS AND LEGACIES

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	<i>Total funds 2016 €</i>
General donations and miscellaneous income	78,152	-	78,152	81,071
Legacies and bequests	40,541	-	40,541	-
Corporate Donations	78,250	142,521	220,771	187,887
Community & Events	20,181	-	20,181	31,272
Regular Givers	33,362	-	33,362	36,693
Private Members Draw	221,728	-	221,728	137,300
	<u>472,214</u>	<u>142,521</u>	<u>614,735</u>	<u>474,223</u>
Total donations and legacies	<u>472,214</u>	<u>142,521</u>	<u>614,735</u>	<u>474,223</u>
<i>Total 2016</i>	<u>298,569</u>	<u>175,654</u>	<u>474,223</u>	

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

3. CHARITABLE ACTIVITIES

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
Department of Environment	-	-	-	20,724
National Lottery Grants (Department of Health, HSE)	-	2,500	2,500	17,900
HSE National Clinical Asthma Programme	-	33,773	33,773	33,080
Gross Lottery Receipts	113,716	-	113,716	66,552
Miscellaneous	12,488	9,915	22,403	29,555
HSE DNC	-	7,643	7,643	7,644
HSE Health Promotion	-	760	760	12,845
HSE PC (Asthma Adviceline)	-	159,190	159,190	45,278
Pobal	-	70,710	70,710	56,884
HSE PC (HCP Programme)	-	4,191	4,191	28,613
Department of Health	-	15,000	15,000	-
HSE Community Outreach	-	7,261	7,261	40,032
HSE Socially Excluded	-	1,436	1,436	13,468
Total	126,204	312,379	438,583	372,575

In respect of the prior year, income of €20,724 received from the Department of Environment and Gross lottery receipts amounting to €66,552 were classified as unrestricted funds. Of the €29,555 miscellaneous income, €12,531 was classified as unrestricted funds. The remaining income received in the prior year was classified as restricted funds.

4. INVESTMENTS

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
Bank deposit interest received	772	-	772	2,325
Total 2016	2,325	-	2,325	

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

5. RAISING FUNDS

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
Asthma Devices	8,666	-	8,666	4,515
Fundraising costs	177,752	-	177,752	206,422
Lottery costs	56,800	-	56,800	34,196
Total	243,218	-	243,218	245,133

All expenditure in the prior year related to unrestricted funds.

6. RESTRUCTURING COSTS

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
Restructuring costs	23,522	-	23,522	59,231

The above restructuring costs in the current and prior year relate to the implementation of the Board approved restructuring plan during 2016 which involved the significant reduction in staff numbers to ensure the protection of the core services of the Society.

7. CHARITABLE ACTIVITIES

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
Health promotion	38,177	234,428	272,605	295,184
Health promotion materials	-	3,628	3,628	6,609
Advocacy & policy	8,105	25,995	34,100	60,605
Research & education	2,638	14,469	17,107	126,473
Communications and campaigns	14,739	103,497	118,236	130,383
Programme Support costs (note 8)	100,729	72,883	173,612	196,455
Governance costs (note 9)	8,696	-	8,696	10,713
Total	173,084	454,900	627,984	826,422

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

8. PROGRAMME SUPPORT COSTS

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
Wages and salaries	4,750	40,952	45,702	57,255
General office expenses	28,564	4,443	33,007	42,858
Premises costs	38,541	414	38,955	39,955
Web support	4,341	4,160	8,501	10,351
HR costs	1,743	-	1,743	5,182
Finance costs	22,790	22,914	45,704	40,854
Total	100,729	72,883	173,612	196,455

9. GOVERNANCE COSTS

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €	Total funds 2016 €
Governance costs including auditors remuneration	8,696	-	8,696	10,713

10. NET INCOME/(EXPENDITURE)

This is stated after charging/(crediting):

	2017 €	2016 €
Depreciation of tangible fixed assets: - owned by the company	3,144	4,471

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

11. STAFF COSTS

The average number of full time equivalent persons employed by the company during the year was as follows:

	2017	2016
	No.	No.
Fundraising and admin	1.00	3.50
Advocacy and communications	2.13	2.00
Health promotion	3.66	3.50
	<u>6.79</u>	<u>9.00</u>

Staff costs were as follows:

	2017	2016
	€	€
Wages and salaries	318,373	419,972
Employers PRSI	32,751	45,269
Pension costs	9,500	11,120
	<u>360,624</u>	<u>476,361</u>

The members of the Board do not receive remuneration for their services as members of the Board. Directly incurred expenses are re-imbursed, if claimed and amounted to €NIL (2016: €NIL)

The number of higher paid employees was:

	2017	2016
	No.	No.
In the band €90,000 - €100,000	1	1
In the band €80,000 - €90,000	-	-
In the band €70,000 - €80,000	-	-
In the band €60,000 - €70,000	-	-
	<u>1</u>	<u>1</u>

This band includes basic pay and excludes employer pension and PRSI contributions.

12. TAXATION

The Charity is exempt from taxation under section 11(6) of the Corporation Tax Act 1976, as a Company.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

13. TANGIBLE FIXED ASSETS

	Fixtures and fittings €	Website Development €	Computer equipment €	Total €
Cost				
At 1 January 2017 and 31 December 2017	57,234	29,299	37,609	124,142
Depreciation				
At 1 January 2017	53,461	29,299	36,402	119,162
Charge for the year	1,937	-	1,207	3,144
At 31 December 2017	55,398	29,299	37,609	122,306
Net book value				
At 31 December 2017	1,836	-	-	1,836
<i>At 31 December 2016</i>	3,773	-	1,207	4,980

In respect of prior year:

	Fixtures and Fittings €	Website Development €	Computer Equipment €	Total €
Cost				
At 1 January 2016 and 31 December 2016	57,234	29,299	37,609	124,142
Depreciation				
At 1 January 2016	51,045	29,299	34,347	114,691
Charge for the year	2,416	-	2,055	4,471
At 31 December 2016	53,461	29,299	36,402	119,162
Net Book Value				
31 December 2016	-	-	-	-
31 December 2016	3,733	-	1,207	4,980
<i>31 December 2015</i>	6,189	-	3,262	9,451

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

14. STOCKS

	2017	2016
	€	€
Finished goods and goods for resale	<u>5,803</u>	<u>9,152</u>

15. DEBTORS

	2017	2016
	€	€
Trade debtors	20,781	81,193
Private members draw	40,811	43,132
Prepayments and accrued income	9,945	14,558
	<u>71,537</u>	<u>138,883</u>

16. CREDITORS: Amounts falling due within one year

	2017	2016
	€	€
Trade creditors	22,174	25,485
PAYE	11,855	9,788
Other creditors	97,508	80,414
Accruals	13,955	29,942
Deferred income	137,563	139,848
	<u>283,055</u>	<u>285,477</u>

17. STATEMENT OF FUNDS

STATEMENT OF FUNDS - CURRENT YEAR

	Balance at 1 January 2017	Income	Expenditure	Balance at 31 December 2017
	€	€	€	€
Unrestricted funds				
General Fund	<u>288,731</u>	<u>599,190</u>	<u>(439,824)</u>	<u>448,097</u>
Restricted funds				
Restricted Funds	<u>-</u>	<u>454,900</u>	<u>(454,900)</u>	<u>-</u>
Total of funds	<u>288,731</u>	<u>1,054,090</u>	<u>(894,724)</u>	<u>448,097</u>

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

17. STATEMENT OF FUNDS (continued)

STATEMENT OF FUNDS - PRIOR YEAR

	<i>Balance at 1 January 2016 €</i>	<i>Income €</i>	<i>Expenditure €</i>	<i>Transfers in/out €</i>	<i>Balance at 31 December 2016 €</i>
Designated funds					
Designated funds	270,000	-	-	(270,000)	-
	<u>270,000</u>	<u>-</u>	<u>-</u>	<u>(270,000)</u>	<u>-</u>
General funds					
General Fund	248,652	400,701	(630,622)	270,000	288,731
	<u>248,652</u>	<u>400,701</u>	<u>(630,622)</u>	<u>270,000</u>	<u>288,731</u>
Total Unrestricted funds	<u>518,652</u>	<u>400,701</u>	<u>(630,622)</u>	<u>-</u>	<u>288,731</u>
Restricted funds					
Restricted Funds	51,742	448,422	(500,164)	-	-
	<u>51,742</u>	<u>448,422</u>	<u>(500,164)</u>	<u>-</u>	<u>-</u>
Total of funds	<u><u>570,394</u></u>	<u><u>849,123</u></u>	<u><u>(1,130,786)</u></u>	<u><u>-</u></u>	<u><u>288,731</u></u>

18. ANALYSIS OF NET ASSETS BETWEEN FUNDS

ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT YEAR

	Unrestricted funds 2017 €	Restricted funds 2017 €	Total funds 2017 €
Tangible fixed assets	1,836	-	1,836
Current assets	729,316	-	729,316
Creditors due within one year	(283,055)	-	(283,055)
	<u>448,097</u>	<u>-</u>	<u>448,097</u>

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

18. ANALYSIS OF NET ASSETS BETWEEN FUNDS (continued)

ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR YEAR

	<i>Unrestricted funds 2016 €</i>	<i>Restricted funds 2016 €</i>	<i>Total funds 2016 €</i>
Tangible fixed assets	4,980	-	4,980
Current assets	569,228	-	569,228
Creditors due within one year	(285,477)	-	(285,477)
	<u>288,731</u>	<u>-</u>	<u>288,731</u>

19. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2017 €	2016 €
Net income/(expenditure) for the year (as per Statement of Financial Activities)	159,366	(281,663)
Adjustment for:		
Interest from investments	(772)	(2,325)
Depreciation of fixed assets	3,144	4,471
Decrease/(increase) in stocks	3,349	(9,151)
Decrease/(increase) in debtors	67,346	(76,769)
(Decrease)/increase in creditors	(2,422)	134,413
Net cash provided by/(used in) operating activities	<u>230,011</u>	<u>(231,024)</u>

20. ANALYSIS OF CASH AND CASH EQUIVALENTS

	2017 €	2016 €
Cash at bank and in hand	651,976	421,193
Total	<u>651,976</u>	<u>421,193</u>

21. PENSION COMMITMENTS

The Company operates defined contribution schemes for the benefit of its staff. The assets of the scheme are held separately from those of the Company in independently administered pension funds. Pension costs amounted to €9,500 (2016: €11,120).

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

22. OPERATING LEASE COMMITMENTS

At 31 December 2017 the total of the Charity's future minimum lease payments under non-cancellable operating leases was:

	2017	2016
	€	€
Amounts payable:		
Within 1 year	29,250	29,250
Between 1 and 5 years	21,938	-
Total	51,188	29,250

23. RELATED PARTY TRANSACTIONS

No related party transactions took place during the year ended 31 December 2017.

24. POST BALANCE SHEET EVENTS

The new CEO, Sarah O'Connor, was appointed and commenced at the Company on 26th February 2018. There have been no other significant events affecting the Company since the year end, which, in the opinion of the Directors, require disclosure in the financial statements.

25. CONTROLLING PARTY

There is no ultimate controlling party. The Directors control the day to day running of the Company on behalf of its members.

26. APPROVAL OF FINANCIAL STATEMENTS

The financial statements were approved by the Board.

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017**

The following information does not form part of the audited financial statements:

APPENDIX – DISCLOSURE OF STATUTORY & CORPORATE SUPPORT

DETAILS OF STATUTORY FUNDING RECIVED IN 2017

Funding agency	Government Department	Amount received/ deferred	Funding was restricted to expenditure on the following	Amount spent in 2017	To be spent/ returned in 2018
HSE Grant Aid, Nat Lottery	Health and Children	€2,500	Asthma Friendly School Programme	€2,500	€Nil
Pobal -Dormant Accounts Fund	Social Protection	€1,367	Parents & Carers Programme	€1,367	€Nil
Pobal- Scheme for support of National Organisations	Environment, Community & Local Government	€69,343	Core staffing	€69,343	€Nil
HSE NAP	Health and Children	€33,773	Support to National Clinical programme for Asthma	€33,773	€Nil
HSE - PC (HCP Programme)	Health and Children	€4,191	Support to the HSE under 6s programme	€4,191	€Nil
HSE - PC (Adviceline)	Health and Children	€159,190	Asthma Adviceline	€159,190	€Nil
HSE Health Promotion	Health and Children	€17,155	Asthma Friendly Sports Club	€760	€16,395
HSE DNC	Health and Children	€7,643	Asthma Service for people in DNC area	€7,643	€Nil
Dept of Health	Health and Children	€15,000	Bubble day	€15,000	€Nil
HSE National Social Inclusion Office	Health and Children	€26,299	Traveller outreach programme	€7,261	€19,038
HSE National Social Inclusion Office	Health and Children	€21,096	Socially excluded outreach	€1,436	€19,660
TOTAL		€357,557		€302,464	€55,093

ASTHMA SOCIETY OF IRELAND
(A company limited by guarantee and not having share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2017

CORPORATE PARTNERS 2017

The Asthma Society would like to thank the following corporate partners for their support for our work in 2017:

Astra Zeneca
Boots Ireland
CPL Fuels
Dyson
Enviroion
GAA
GSK
Malones of Dublin
Mundipharma
Novartis
Nuwave
Teva